Filing Flows › 10x Genomics (TXG) › Q3 2025
10x Genomics (TXG) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
10x Genomics (TXG) reported revenue of $149M for the third quarter 2025 (Q3 2025), -2% from a year earlier and -14% from the quarter before. Operating margin was -21.6%, net loss $27.5M (18.4% of revenue).
10x Genomics, Q3 2025: revenue $149M (-2% year over year), operating margin -21.6%, net loss $27.5M, operating cash flow $43.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $149M | -14% | -2% |
| Operating profit | −$32.2M | -207% | — |
| Net earnings | −$27.5M | -180% | — |
| Operating cash flow | $43.2M | +144% | +100% |
| Free cash flow | $42.5M | +164% | +140% |
What changed
Revenue was $149.0M in Q3 2025, down 2% year over year and down 14% from the previous quarter. Chromium was the largest line at 62% of revenue. Spatial lost $4.3M year over year (down 38%), 164% of the total change.
Gross margin was 67.3%, down 2.8 points from a year earlier. Operating costs exceeded revenue by $32.2M, an operating margin of -21.6%. Operating expenses fell 10% while revenue fell 2%. The quarter ended with a net loss of $27.5M, after a profit of $34.5M the previous quarter.
Operating cash flow was $43.2M (up 100% year over year). Non-cash charges added back $10.3M of depreciation and amortization and $25.3M of share-based compensation. Working capital and other items added $35.1M. Capital expenditures of $687K left free cash flow of $42.5M.
Questions
What was 10x Genomics' revenue in the third quarter 2025?
10x Genomics (TXG) reported revenue of $149M for the third quarter 2025 (Q3 2025), -2% from a year earlier and -14% from the quarter before.
Was 10x Genomics profitable in the third quarter 2025?
Operating loss was $32.2M (-21.6% of revenue) and net loss $27.5M.
Source: 10x Genomics 10-Q on SEC EDGAR.